Literature DB >> 15280456

Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism.

Steven C Pettit1, Lorraine E Everitt, Sumana Choudhury, Ben M Dunn, Andrew H Kaplan.   

Abstract

Processing of the GagPol polyprotein precursor of human immunodeficiency virus type 1 (HIV-1) is a critical step in viral assembly and replication. The HIV-1 protease (PR) is translated as part of GagPol and is both necessary and sufficient for precursor processing. The PR is active only as a dimer; enzyme activation is initiated when the PR domains in two GagPol precursors dimerize. The precise mechanism by which the PR becomes activated and the subsequent initial steps in precursor processing are not well understood. However, it is clear that processing is initiated by the PR domain that is embedded within the precursor itself. We have examined the earliest events in precursor processing using an in vitro assay in which full-length GagPol is cleaved by its embedded PR. We demonstrate that the embedded, immature PR is as much as 10,000-fold less sensitive to inhibition by an active-site PR inhibitor than is the mature, free enzyme. Further, we find that different concentrations of the active-site inhibitor are required to inhibit the processing of different cleavage sites within GagPol. Finally, our results indicate that the first cleavages carried out by the activated PR within GagPol are intramolecular. Overall, our data support a model of virus assembly in which the first cleavages occur in GagPol upstream of the PR. These intramolecular cleavages produce an extended form of PR that completes the final processing steps accompanying the final stages of particle assembly by an intermolecular mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280456      PMCID: PMC479095          DOI: 10.1128/JVI.78.16.8477-8485.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

Review 1.  Binding energy, specificity, and enzymic catalysis: the circe effect.

Authors:  W P Jencks
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1975

2.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  The use of native T7 DNA polymerase for site-directed mutagenesis.

Authors:  K Bebenek; T A Kunkel
Journal:  Nucleic Acids Res       Date:  1989-07-11       Impact factor: 16.971

4.  Complete nucleotide sequences of functional clones of the AIDS virus.

Authors:  L Ratner; A Fisher; L L Jagodzinski; H Mitsuya; R S Liou; R C Gallo; F Wong-Staal
Journal:  AIDS Res Hum Retroviruses       Date:  1987       Impact factor: 2.205

5.  Standardized and simplified nomenclature for proteins common to all retroviruses.

Authors:  J Leis; D Baltimore; J M Bishop; J Coffin; E Fleissner; S P Goff; S Oroszlan; H Robinson; A M Skalka; H M Temin
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

6.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.

Authors:  T Jacks; M D Power; F R Masiarz; P A Luciw; P J Barr; H E Varmus
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

7.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

8.  Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease.

Authors:  A G Tomasselli; M K Olsen; J O Hui; D J Staples; T K Sawyer; R L Heinrikson; C S Tomich
Journal:  Biochemistry       Date:  1990-01-09       Impact factor: 3.162

9.  Sensitive, soluble chromogenic substrates for HIV-1 proteinase.

Authors:  A D Richards; L H Phylip; W G Farmerie; P E Scarborough; A Alvarez; B M Dunn; P H Hirel; J Konvalinka; P Strop; L Pavlickova
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

10.  Human immunodeficiency virus (HIV) type 1 transframe protein can restore activity to a dimerization-deficient HIV protease variant.

Authors:  Nathalie Dautin; Gouzel Karimova; Daniel Ladant
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more
  70 in total

1.  The nature of the N-terminal amino acid residue of HIV-1 RNase H is critical for the stability of reverse transcriptase in viral particles.

Authors:  Guney Boso; Claes Örvell; Nikunj V Somia
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  Foamy virus Pol protein expressed as a Gag-Pol fusion retains enzymatic activities, allowing for infectious virus production.

Authors:  Eun-Gyung Lee; Amber Sinicrope; Dana L Jackson; Shuyuarn F Yu; Maxine L Linial
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

3.  Analysis of human immunodeficiency virus matrix domain replacements.

Authors:  Isabel Scholz; Amelia Still; Tenzin Choesang Dhenub; Kelsey Coday; Mike Webb; Eric Barklis
Journal:  Virology       Date:  2007-11-08       Impact factor: 3.616

4.  Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication.

Authors:  Andreas Leiherer; Christine Ludwig; Ralf Wagner
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

5.  Nine crystal structures determine the substrate envelope of the MDR HIV-1 protease.

Authors:  Zhigang Liu; Yong Wang; Joseph Brunzelle; Iulia A Kovari; Ladislau C Kovari
Journal:  Protein J       Date:  2011-03       Impact factor: 2.371

6.  Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors.

Authors:  John M Louis; Annie Aniana; Irene T Weber; Jane M Sayer
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-16       Impact factor: 11.205

7.  Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

Authors:  Hironori Hayashi; Nobutoki Takamune; Takashi Nirasawa; Manabu Aoki; Yoshihiko Morishita; Debananda Das; Yasuhiro Koh; Arun K Ghosh; Shogo Misumi; Hiroaki Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

8.  Analysis and characterization of dimerization inhibition of a multi-drug-resistant human immunodeficiency virus type 1 protease using a novel size-exclusion chromatographic approach.

Authors:  David A Davis; Irene R Tebbs; Sarah I Daniels; Stephen J Stahl; Joshua D Kaufman; Paul Wingfield; Michael J Bowman; Jean Chmielewski; Robert Yarchoan
Journal:  Biochem J       Date:  2009-04-15       Impact factor: 3.857

9.  Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.

Authors:  Arun K Ghosh; Jacqueline N Williams; Rachel Y Ho; Hannah M Simpson; Shin-Ichiro Hattori; Hironori Hayashi; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Hiroaki Mitsuya
Journal:  J Med Chem       Date:  2018-10-24       Impact factor: 7.446

Review 10.  Molecular mechanisms of FIV infection.

Authors:  John H Elder; Magnus Sundstrom; Sohela de Rozieres; Aymeric de Parseval; Chris K Grant; Ying-Chuan Lin
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.